JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on December 21, 2007; DOI: 10.1124/jpet.107.131318

0022-3565/08/3243-1064-1072$20.00
JPET 324:1064-1072, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.131318v1
324/3/1064    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Demeule, M.
Right arrow Articles by Béliveau, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demeule, M.
Right arrow Articles by Béliveau, R.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Identification and Design of Peptides as a New Drug Delivery System for the Brain

Michel Demeule, Anthony Régina, Christian Ché, Julie Poirier, Tran Nguyen, Reinhard Gabathuler, Jean-Paul Castaigne, and Richard Béliveau

Laboratoire de Médecine Moléculaire, Centre d'Hémato-Oncologie, Hôpital Ste-Justine-Université du Québec à Montréal, Montréal, Québec, Canada (A.R., J.P., R.B.); and Angiochem, Montreal, Quebec, Canada (M.D., C.C., T.N., R.G., J.-P.C.)

By controlling access to the brain, the blood-brain barrier (BBB) restricts the entry of proteins and potential drugs to cerebral tissues. We demonstrate here the transcytosis ability of aprotinin and peptides derived from Kunitz domains using an in vitro model of the BBB and in situ brain perfusion. Aprotinin transcytosis across bovine brain capillary endothelial cell (BBCEC) monolayers is at least 10-fold greater than that of holo-transferrin. Sucrose permeability was unaffected by high concentrations of aprotinin, indicating that transcytosis of aprotinin was unrelated to changes in the BBCEC monolayer integrity. Alignment of the amino acid sequence of aprotinin with the Kunitz domains of human proteins allowed the identification and design of a family of peptides, named Angiopeps. These peptides, and in particular Angiopep-2, exhibit higher transcytosis capacity and parenchyma accumulation than aprotinin. Overall, these results suggest that these Kunitz-derived peptides could be advantageously used as a new brain delivery system for pharmacological agents that do not readily enter the brain.

Received September 13, 2007; accepted December 20, 2007.

Address correspondence to: Dr. Richard Béliveau, Laboratoire de Médecine Moléculaire, Centre d'Hémato-Oncologie, Hôpital Ste-Justine-Université du Québec à Montréal, Montréal, QC, Canada H3C 3P8. E-mail: beliveau.richard{at}uqam.ca






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.